$MRNA

Novavax shares surge 13.16% Friday, tracking Moderna's flu vaccine milestone. Q1 sales beat estimates at $139.51M despite net loss reversal.

Moderna stock rises after positive Phase 1 hantavirus vaccine data, with analysts raising price targets amid signs of mRNA platform diversification beyond COVID.

Moderna beats revenue estimates with $389M vs. $227.97M consensus but shares fall 2.05% due to $2.22 per share litigation settlement charge.

S&P 500 hits record 7,209.01 after best April since 2020. Futures point higher for May 1 as earnings strength and easing geopolitical tensions fuel bullish sentiment.

$ISCV offers lower fees (0.06%) and higher yield (1.9%), while $IWN provides better liquidity and recent returns (48.6% vs 37.5%). Choose based on investment horizon.

Eli Lilly, Vertex Pharmaceuticals, and Intuitive Surgical possess durable competitive moats—patent protection and market dominance—supporting sustained earnings growth through the 2030s.

Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.

Immatics' PRAME-directed TCR therapy achieves deep remission in advanced pediatric cancer patient, validating engineered T-cell approach in solid tumors.

Sysco, McCormick, and Eli Lilly announce $78B in major acquisitions spanning foodservice, consumer staples, and pharma, signaling significant industry consolidation.

Iran's peace signal triggers tech rally. Nasdaq 100 jumps 3.2%, WTI crude falls 2% to $100/barrel. Mega-cap tech gains $950 billion.

Moderna stock surges 70% in 2026 on vaccine and cancer therapy pipeline expansion, but $2.8B losses amid $1.9B revenue temper bullish sentiment.

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

$VBR dominates $ISCV in scale ($62.3B vs $594.6M) with better liquidity, while $ISCV edges performance (18.3% vs 17.9%) with higher yield.

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.

Moderna settles $2.25B patent dispute, surges 15.99%. Analysis identifies 9 biotech stocks trading 27-65% below fair value with 31-251% upside potential.

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.

Moderna shifts from pandemic revenues toward diversified pipeline including seasonal vaccines and oncology treatments, targeting cash breakeven by 2028 amid FDA progress on flu vaccine candidate.

Large-cap stocks rallied on strong earnings and corporate actions. First Majestic Silver led with 25% gains, joined by Moderna and Global Payments on positive results.